Lee BioSolutions Supplies Highest Quality Blood Cell Cancer Markers

Share Article

Lee BioSolutions Inc, an international manufacturer, producer and supplier of high purity finished human and animal proteins announces increased production of beta 2 Microglobulin

President

Lee BioSolutions Inc, an international manufacturer, producer and supplier of high purity finished proteins and antigens announces increased production of beta 2 Microglobulin . The St. Louis-based healthcare- biotechnology firm has developed a unique proprietary process to effectively and efficiently purify B2M in bulk. As a result, Lee is now is a preferred producer for researchers and diagnostic companies to supply this critical tumor marker for multiple myelomas and lymphomas.

Beta 2 Microglobulin is an important blood plasma protein used for detecting some blood cell cancers such as lymphomas and multiple myelomas and for detecting kidney damage. B2M is used for prognosis because it is found on the surface of many cells, including lymphocytes, and in small amounts in the blood and urine.    According to the CDC, there are over 10,000 deaths of multiple myeloma per year and over 20,000 people dying from lymphoma just in the United States alone. Lymphoma is the most common form of blood cancer in the developed world.    

“ We feel that Lee Biosolutions is on the forefront of Blood Cell Cancer research by supplying highly purified markers such as Beta 2 Microglobulin to the research community and clinical diagnostic market. A B2M Test measures the level of B2M in the blood or urine and is one of the tools used for identifying disease activity and tumor burden. With continued improvements in screening, diagnosis and treatment of blood cancers and kidney damage more individuals are able to manage their disease earlier and live longer .” said Burton Lee, President of Lee Biosolutions.

About Lee BioSolutions, Inc.
Lee BioSolutions is an international producer and supplier of high purity finished proteins. Headquartered in St. Louis and founded in 2002, the healthcare biotechnology firm serves academic and scientific researchers as well as IVD manufacturers worldwide. Lee BioSolutions produces and processes finished and intermediate proteins used in drug discovery and development , clinical diagnosis and product testing. These include Alpha Feto Protein used in detection of liver cancer and germ cell tumors, Beta 2 Microglobulin used to detect multiple myeloma, chronic lymphocytic leukemia and some lyophomas, Thyroglobulin for detecting Thyroid Cancer, and Lactate Dehydrogenase used to assess state and prognosis of Germ cell tumors.    The company is ISO 9001:2008 certified, FDA registered and approved by APHIS for exporting . To learn more about Lee BioSolutions visit http://www.LeeBio.com or call 314-968-1091.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Burton Lee
Visit website